I write about the science and implementation of psychedelics as medicines. Join to learn alongside me and make the future happen sooner!
The Bloom 138 - The Year of Lucidity
Happy New Year! Wow, what a year it's been for psychedelic research. I've added 288 psychedelic articles to the database and over 1000 more to the link overviews. The monthly recaps total over 16.500 words (see the one for December here). Looking up from my naval-gazing, it's also been a pivotal year with MAPS submitting the Phase III results to the FDA and 11.000 people gathering in Denver for Psychedelic Science. In 2024, we'll get more clarity on the future of 'psychedelics as medicines'. Will MDMA-AT for PTSD be approved? And will all infrastructure pieces (training, reimbursement, approval, etc.) fall into place in time? (I'll continue increasing my coverage of these points) I'm in no doubt that psychedelic research will - once again - see a record year of exciting results. But will the companies (for-/non-profit) be there to commercialise the findings? Or will decriminalisation and underground use remain the access routes to psychedelic healing? I'm excited for 2024 and hope to see you there on the journey! (let's meet at ICPR, use code BLOSSOM100 for €100 discount) Floris - Founder of Blossom ps If there's one other newsletter that helps me download the latest in psychedelics in under 10 minutes it's Tricycle Day. Next to research, Henry informs 36k+ readers on policy and business in a fun newsletter. Check out Tricycle Day! Latest Psychedelic Research1 Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trialThis open-label, single-ascending, fixed-order dose-response study (n=27) investigates the safety and tolerability of inhaled DMT. The healthy volunteers received varying doses of inhaled DMT (5-60mg). Preliminary findings indicate dose-dependent increases in intensity, valence, and perceptual ratings, with no significant safety concerns, suggesting inhaled DMT as a potentially efficient and safe administration method.
2 The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world dataThis combined analysis of two cohorts (n=311) compared intravenous ketamine (KET-IV) and intranasal esketamine (ESK-NS) in the treatment of Treatment-Resistant Depression (TRD). The study found that KET-IV (n=171) had larger effect sizes and higher response rates than ESK-NS (n=140), although both significantly reduced depressive symptoms. Despite KET-IV having more reported side effects, its discontinuation rate due to adverse events was not significantly higher than ESK-NS. 3 Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational studyThis survey (n=1022) investigated the correlation between set and setting variables in psychedelic therapy with psychopathology, well-being, and personality. Findings suggest that growth motivations, natural settings, and the presence of significant others predict positive outcomes. In contrast, problematic motivations are associated with greater psychopathology and lower well-being. More new research |
New on Blossom1 The Long Road to Access – Psychedelics as MedicinesIt's a long and bumpy road ahead before we see psychedelics as medicines generally accepted. Here is my take on the recently presented pyramid by Tadeusz Hawrot. 2 Psychedelic Research Recap December 2023December's psychedelic research looked at group therapy, personality, costs and microdosing LSD. We added 22 articles to the database. 3 Psychedelic Research Links December 2023All the other papers that have come out this month we didn't add to the database.
SpotlightNo spotlight this week. |
Molenvaart 76, Anna Paulowna, NH 1761AL |
Floris from Blossom
I write about the science and implementation of psychedelics as medicines. Join to learn alongside me and make the future happen sooner!
The Bloom #148 Free Edition rolling Over the last week, it seems that psychedelic research is coming at us faster than ever before. Researchers re-analysed data from a single-blind study of psilocybin-assisted therapy for depression and found that psychological flexibility, mindfulness, and living according to one’s values improved, even four months after the study's conclusion. Next to academic research, I'm seeing an uptick in publications from the psychedelic drug developers, including a...
The Bloom #147 Free Edition the EMA workshop Editor note: My apologies for not getting this email to you last week, I see that it accidentally was stuck in draft - so you are getting this email and the one for this week just a few minutes apart How do psychedelics work? Some may say we have all the answers already, and that all the research currently happening is just an exercise in writing down wisdom that's already present in the wider world outside of academia. Others, notably the...
The Bloom #146 Free Edition open design The psychedelic conference season is just around the corner. I've just updated our Events page, which should now give a good overview of a variety of conferences that are happening in the coming 1.5 years. In-person conferences include ICPR, which has just added a policy-focused day (Pathways of Access Summit) at the start of the conference; with the code BLOSSOM50, you can get a €50 discount. Online you can also bump into me at the Psychedelics and...